MCL Literature Feed

Combining time-limited ibrutinib with CTL019 CAR-T in relapsed/refractory MCL achieved an 80% CR rate with manageable toxicity, showing efficacy even in BTKi-pretreated and TP53-mutated patients.

A Mendelian randomization study provides causal evidence that genetically predicted longer telomere length increases the risk of developing MCL, suggesting a role for enhanced cellular proliferation in pathogenesis.

An AI model using ensemble convolutional neural networks distinguished MCL from CLL and FL on pathology images with 99% accuracy, offering a potential tool for automated histopathological diagnosis.

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

This multi-modal single-cell atlas of the human tonsil provides a high-resolution map of normal B-cell development, enabling a deeper understanding of MCL's cellular origins and heterogeneity.

Targeting the epigenetic modifier KDM5 shows preclinical activity in mantle cell lymphoma, identifying a novel therapeutic vulnerability for potential future treatments.

In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

This case report describes mantle cell lymphoma presenting atypically as erosive duodenitis, highlighting a rare gastrointestinal manifestation that can mimic more common inflammatory conditions.

This case report identifies a rare, leukemic, cyclin D1/SOX11-negative MCL driven by a CCND3::IGH rearrangement, highlighting a diagnostic pitfall and the importance of molecular testing in atypical cases.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

This preclinical study identifies that the miR-17-92 cluster suppresses the tumor suppressor BTG2, leading to B-cell receptor signaling overactivation and suggesting BTG2 as a prognostic biomarker.

PLSCR1 induction by retinoic acid/interferon-α enhances immunogenic cell death in MCL, improving the efficacy of dendritic cell-based vaccines by boosting anti-tumor T-cell responses in vitro.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This case report describes a rare presentation of mantle cell lymphoma as a large right atrial mass, highlighting the potential for significant cardiac involvement and informing differential diagnosis.

Ibrutinib plus venetoclax shows high efficacy (83% CR) and deep MRD negativity with good tolerability in Japanese patients with relapsed/refractory MCL, supporting its use in this population.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This 2024 review of 80 FDA-approved kinase inhibitors highlights pirtobrutinib's recent approval for relapsed/refractory MCL, contextualizing its properties within the broader landscape of targeted therapies.

This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.

This preclinical study identifies the protease SENP3 as a novel driver of MCL proliferation via the Wnt10a signaling pathway, presenting SENP3 as a potential new therapeutic target.

Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.

This retrospective study of 134 patients demonstrates that adding a BTK inhibitor to chemotherapy improves efficacy and prolongs progression-free survival in relapsed/refractory MCL.

Preclinically, chlorambucil and ibrutinib show synergistic apoptosis in an MCL cell line, suggesting a novel chemo-BTKi combination strategy potentially mediated by inhibiting the AKT signaling pathway.

A novel BRAF N581S mutation was identified in mantle cell lymphoma, expanding the known genomic landscape and suggesting a potential new therapeutic target for this rare patient subset.

This case report documents the first complete response of frontline CNS-involved MCL to single-agent acalabrutinib, suggesting a potential chemotherapy-free, CNS-penetrant option for this high-risk population.

An MRD-driven, finite-duration venetoclax-lenalidomide-rituximab regimen is effective in relapsed/refractory MCL, even post-BTKi, allowing nearly half of patients to stop therapy and maintain durable molecular remissions.